Clinical use of new and repurposed drugs: the role and contribution of the ERS collaborative projects Source: International Congress 2017 – In the frontline of the fight against tuberculosis Year: 2017
Establishing new treatments: the role of RCTs Source: Virtual Congress 2020 – Tuberculosis: learning from the WHO global health emergencies Year: 2020
Key role of patients in clinical trials Source: Research Seminar 2013 - ERS Presidential Summit on Research gaps, patient needs and innovative solutions: a forward look on lung health research Year: 2013
New clinical research strategies in thoracic oncology: clinical trial design, adaptive, basket and umbrella trials, new end-points and new evaluations of response Source: Eur Respir Rev 2014; 23: 367-378 Year: 2014
SARS-CoV-2 disrupts clinical research: the role of a rare disease-specific trial network Source: Eur Respir J, 56 (3) 2002114; 10.1183/13993003.02114-2020 Year: 2020
Lots of promising targets and biomarkers, but how can we deliver the next generation of severe asthma trials? Source: International Congress 2019 – Beyond T2 mechanisms in asthma: who are the other players? Year: 2019
COPD mechanisms: novel aspects and implications for new therapies Source: ERS Live 2007 Year: 2007
Do the current endpoints in IPF clinical trials allow good regulatory decisions to be made? Source: International Congress 2014 – Ceremony for the ERS Rare Pulmonary Disease Research Award 2014 followed by the symposium "Challenges in endpoints for rare lung diseases" Year: 2014
The impact of a new recruitment strategy to improve recruitment of participants to research studies Source: International Congress 2019 – How to guide patients to reach a balance between costs and personal needs: quality indicators of effectiveness Year: 2019
What could we learn from ongoing therapeutic trials? Source: ERS Research Seminar Year: 2015
Characterisation of clinical phenotypes is mandatory for the development of new drugs Source: Research Seminar 2014 - Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD Year: 2014
The future of translational lung cancer research: from classical randomised controlled trials to innovative platform trials Source: International Congress 2018 – New drugs, strategies and research designs for advanced non-small cell lung cancer Year: 2018
Who should receive which biologic and why? Current and future approaches in severe asthma patients Source: Virtual Congress 2021 – Linking scientific mechanisms to recent clinical therapeutic advances in airway disease: why, who, when and what? Year: 2021
A new model for clinical trials to address the COVID-19 emergency Source: Breathe, 16 (2) 200220; 10.1183/20734735.0220-2020 Year: 2020
At the interface: the translational science supporting the clinical use of anti-cytokine therapy Source: International Congress 2018 – New biologics for asthma: which patients, which agents, which results, at what cost? Year: 2018
How do I manage NTM patients? Incorporating key learning from clinical cases Source: ERS Course 2015 Year: 2015
Large trials, new knowledge: the changing face of COPD management Source: Eur Respir J 2015; 45: 1692-1703 Year: 2015